# US 2022/0064267 A1 · Antibodies and methods for treatment of lyssavirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064267 A1
- Document ID: US20220064267A1
- Status: Published application
- Kind: A1
- Application number: 17/286,406
- Filed: 2019-10-18
- Published: 2022-03-03
- Earliest claimed: 2018-10-19
- Applicants: Humabs Biomed SA; Institut Pasteur
- Inventors: Davide CORTI; Hervé BOURHY; Florian SONTHONAX; Gabriel LEPOUSEZ; Guilherme DIAS DE MELO
- Web page: https://patentgrep.com/patent/US20220064267A1

## CPC

- A61K 39/12: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C07K 16/10: RNA viruses
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides antibodies, and antigen-binding fragments thereof, that potently neutralize lyssavirus infection and the use of such antibodies. In particular, the invention provides methods of treatment of lyssavirus infection, such as rabies.

## Claims

### Claim 1

A method of treating a lyssavirus infection in a subject, the method comprising administering an anti-lyssavirus antibody, or an antigen-binding fragment thereof into a central nervous system (CNS) and peripherally.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, into the CNS, peripherally, or both for the first time at least five days, at least six days, at least seven days, or at least eight days after exposure of the subject to a lyssavirus.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, into the CNS, peripherally, or both for the first time after symptoms of lyssavirus infection occur in the subject.

### Claim 7 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, peripherally and into the CNS on the same day, at about the same time, or concurrently.

### Claim at position 6

8-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, comprising a single peripheral administration of the antibody, or the antigen-binding fragment thereof.

### Claim 11 (depends on 1)

The method of claim 1, comprising repeatedly administering the antibody, or the antigen-binding fragment thereof peripherally.

### Claim 12 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, into the CNS continuously for at least 15 minutes, at least 30 minutes, at least 1 hour, at least 6 hours, at least 12 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, or at least 5 days.

### Claim at position 10

13-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, into the CNS daily or every second day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 days.

### Claim 23 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, into the CNS intrathecally, intracerebroventricularly, intracerebrally, epidurally, transnasally, intranasally, or perspinally.

### Claim 24 (depends on 1)

The method of claim 1, comprising peripherally administering the antibody, or the antigen-binding fragment thereof systemically or locally.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, comprising peripherally administering the antibody, or the antigen-binding fragment thereof intramuscularly, intravenously, intradermally, or subcutaneously.

### Claim 27 (depends on 1)

The method of claim 1, wherein the lyssavirus infection is rabies and the anti-lyssavirus antibody, or the antigen-binding fragment thereof, is an anti-RABV antibody or an antigen-binding fragment thereof.

### Claim 28 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen-binding fragment thereof, binds to lyssavirus glycoprotein G.

### Claim 29

(canceled)

### Claim 30 (depends on 27)

The method of claim 27, wherein the antibody, or the antigen-binding fragment thereof, binds to antigenic site I or antigenic site III of glycoprotein G of RABV.

### Claim 31 (depends on 1)

The method of claim 1, wherein the method comprise administering a first anti-lyssavirus antibody, or an antigen-binding fragment thereof, in combination with a second anti-lyssavirus antibody, or an antigen-binding fragment thereof.

### Claim 32 (depends on 31)

The method of claim 31, comprising administering the first and second anti-lyssavirus antibodies, or the antigen-binding fragments thereof, in combination in the same pharmaceutical composition.

### Claim 33

(canceled)

### Claim 34 (depends on 31)

The method of claim 31, wherein the first anti-lyssavirus antibody, or the antigen-binding fragment thereof, binds to antigenic site I of glycoprotein G of RABV and the second anti-lyssavirus antibody, or the antigen-binding fragment thereof, binds to antigenic site III of glycoprotein G of RABV.

### Claim 35 (depends on 31)

The method of claim 31, comprising administering the first anti-lyssavirus antibody, or the antigen-binding fragment thereof, and the second anti-lyssavirus antibody, or the antigen-binding fragment thereof, in combination at equimolar amounts.

### Claim 36 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen-binding fragment thereof, comprises a monoclonal antibody, a human antibody, a purified antibody, a single chain antibody, a Fab, a Fab′, a F(ab′)2, a Fv, and/or a scFv.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen-binding fragment thereof, neutralizes lyssavirus infection by (i) RABV and (ii) at least 50% of non-RABV lyssaviruses selected from the group consisting of DUVV, EBLV-1, EBLV-2, ABLV, IRKV, KHUV, ARAV, LBV, MOK, SHIV, BBLV, WCBV and IKOV with an IC50 of less than 10000 ng/ml.

### Claim 39

(canceled)

### Claim 40 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen-binding fragment thereof, comprises: (i) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 93-97 and 99 or of SEQ ID NOs: 93-96 and 98-99, respectively; (ii) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 165-169 and 171 or of SEQ ID NOs: 165-168 and 170-171, respectively; (iii) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 1-5 and 7 or of SEQ ID NOs: 1-4 and 6-7, respectively; (iv) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 19-23 and 25 or of SEQ ID NOs: 19-22 and 24-25, respectively; (v) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 37-41 and 43 or of SEQ ID NOs: 37-40 and 42-43, respectively; (vi) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 55-59 and 61 or of SEQ ID NOs: 55-58 and 60-61, respectively; (vii) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 75-79 and 81 or of SEQ ID NOs: 75-78 and 80-81, respectively; (viii) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 111-115 and 117 or of SEQ ID NOs: 111-114 and 116-117, respectively; (ix) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 129-133 and 135 or of SEQ ID NOs: 129-132 and 134-135, respectively; (x) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 147-151 and 153 or of SEQ ID NOs: 147-150 and 152-153, respectively; (xi) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 183-187 and 189 or of SEQ ID NOs: 183-186 and 188-189, respectively; or (xii) heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 201-205 and 207 or of SEQ ID NOs: 201-204 and 206-207, respectively.

### Claim 41 (depends on 40)

The method of claim 40, wherein the antibody, or the antigen-binding fragment thereof, comprises heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences of SEQ ID NOs: 93-97 and 99 or of SEQ ID NOs: 93-96 and 98-99, respectively.

### Claim 42

(canceled)

### Claim 43 (depends on 40)

The method of claim 40, wherein the antibody, or the antigen-binding fragment thereof, comprises: (i) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 107 and a light chain variable region having the amino acid sequence of SEQ ID NO: 108; or (ii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 179 and a light chain variable region having the amino acid sequence of SEQ ID NO: 180; or (iii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 15 and a light chain variable region having to the amino acid sequence of SEQ ID NO: 16; or (iv) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 33 and a light chain variable region having the amino acid sequence of SEQ ID NO: 34; or (v) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 51 and a light chain variable region having amino acid sequence of SEQ ID NO: 52; or (vi) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 69 and a light chain variable region having the amino acid sequence of SEQ ID NO: 71; or (vii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 70 and a light chain variable region having the amino acid sequence of SEQ ID NO: 71; or (viii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 89 and a light chain variable region having the amino acid sequence of SEQ ID NO: 90; or (ix) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 125 and a light chain variable region having the amino acid sequence of SEQ ID NO: 126; or (x) a heavy chain variable region the amino acid sequence of SEQ ID NO: 143 and a light chain variable region having the amino acid sequence of SEQ ID NO: 144; or (xi) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 161 and a light chain variable region having the amino acid sequence of SEQ ID NO: 162; or (xii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 197 and a light chain variable region having the amino acid sequence of SEQ ID NO: 198; or (xiii) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 215 and a light chain variable region having the amino acid sequence of SEQ ID NO: 216.

### Claim 44 (depends on 43)

The method of claim 43, wherein the antibody, or the antigen-binding fragment thereof, comprises a heavy chain variable region the amino acid sequence of SEQ ID NO: 107 and a light chain variable region having the amino acid sequence of SEQ ID NO: 108 or a heavy chain variable region having the amino acid sequence of SEQ ID NO: 179 and a light chain variable region having the amino acid sequence of SEQ ID NO: 180.

### Claim at position 34

45-60. (canceled)

### Claim 61 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, in combination with an anti-lyssavirus vaccine, an antiviral agent, interferon-alpha and/or ketamine.

### Claim 62 (depends on 61)

The method of claim 61, wherein the anti-lyssavirus vaccine is a rabies vaccine or the antiviral agent ribavirin.

### Claim 63

(canceled)

### Claim 64 (depends on 1)

The method of claim 1, comprising administering the antibody, or the antigen-binding fragment thereof, without concomitant and/or subsequent administration of an anti-lyssavirus vaccine.

### Claim at position 39

65-71. (canceled)

### Claim 72

An anti-lyssavirus antibody, or an antigen-binding fragment thereof, comprising an Fc moiety comprising a CH2 domain and a CH2 L4A mutation and/or a CH2 L5A mutation.

### Claim at position 41

73-96. (canceled)

### Claim 97 (depends on 72)

A nucleic acid molecule comprising a polynucleotide encoding the antibody, or the antigen binding fragment thereof, according claim 72.

### Claim 98

(canceled)

### Claim 99 (depends on 97)

A vector comprising the nucleic acid molecule according to claim 97.

### Claim 100 (depends on 97)

A cell expressing the antibody, or the antigen binding fragment thereof, according to claim 97.

### Claim 101 (depends on 1)

A pharmaceutical composition comprising the antibody, or the antigen binding fragment thereof, according claim 1, and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim at position 47

102-127. (canceled)

### Claim 128 (depends on 1)

The method of claim 1, wherein the antibody, or an antigen-binding fragment thereof, comprises an Fc moiety comprising a CH2 domain and a CH2 L4A mutation and/or a CH2 L5A mutation.

### Claim 129

A method of treating a lyssavirus infection in a subject, the method comprising administering an anti-lyssavirus antibody, or an antigen-binding fragment thereof, into a central nervous system of the subject, wherein the subject has been administered, is being administered, or will be administered the anti-lyssavirus antibody, or an antigen-binding fragment thereof peripherally.

### Claim 130

A method of treating a lyssavirus infection in a subject, the method comprising administering an anti-lyssavirus antibody, or an antigen-binding fragment thereof, peripherally in the subject, where the anti-lyssavirus antibody, or antigen-binding fragment thereof has been administered, is being administered, or will be administered into a central nervous system (CNS) of the subject.
